Poxel SA (LTS:0RA2)
€ 0.1424 0 (0%) Market Cap: 7.53 Mil Enterprise Value: 52.36 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 8/100

Poxel S.A. - Special Call Transcript

Oct 01, 2020 / 04:00PM GMT
Release Date Price: €6.83 (+2.02%)
Operator

Ladies and gentlemen, welcome to Poxel PXL770 Phase IIa Trial Results Announcement.

I now hand over the call to Mrs. Jonae Barnes, Senior Vice President, Investor Relations, Corporate Communications and Public Relations. Madam, please go ahead.

Jonae R. Barnes
Poxel S.A. - SVP, IR, Corporate Communications & Public Relations

Good afternoon, everyone, and welcome to our conference call today to review the results from the PXL770 Phase IIa trial. I'm Jonae Barnes, Senior Vice President, Investor Relations, Corporate Communications and Public Relations. With me on the call, Thomas Kuhn, CEO; Pascale Fouqueray, Executive Vice President, Clinical Development and Regulatory Affairs; David Moller, Executive Vice President and Chief Scientific Officer; and Julie Dubourg, Medical Director, Clinical Development. They will all be available for Q&A after our call is complete.

Earlier today, we issued a press release for the PXL770 Phase IIa results. For those of you who don't have a copy, you can access it in the Investor Relations section of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot